Antitumor activity of haloacetylphenothiazines against ascites sarcoma-180.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D002066:Busulfan / Q000627:therapeutic use / Q000633:toxicity; D003520:Cyclophosphamide / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D007461:Iodoacetates / Q000627:therapeutic use / Q000633:toxicity; D051379:Mice; D009368:Neoplasm Transplantation; D010640:Phenothiazines / Q000627:therapeutic use* / Q000633:toxicity; D010885:Pipobroman / Q000627:therapeutic use / Q000633:toxicity; D012510:Sarcoma 180 / Q000188:drug therapy*; D013852:Thiotepa / Q000627:therapeutic use / Q000633:toxicity
D000970:Antineoplastic Agents; D007461:Iodoacetates; D010640:Phenothiazines; D010885:Pipobroman; D003520:Cyclophosphamide; D013852:Thiotepa; D002066:Busulfan